Stay updated on MND-2119 Long-Term Safety/Efficacy in Hypertriglyceridemia Clinical Trial

Sign up to get notified when there's something new on the MND-2119 Long-Term Safety/Efficacy in Hypertriglyceridemia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MND-2119 Long-Term Safety/Efficacy in Hypertriglyceridemia Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-06-13T21:57:08.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an improvement in the target median progression-free survival (PFS) from 3.0 months to 5.0 months in patients with metastatic urothelial carcinoma receiving pembrolizumab + nab-paclitaxel after chemotherapy failure.
    Difference
    0.1%
    Check dated 2024-06-06T14:34:31.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, such as the requirement to provide informed consent and be at least 18 years old. Previously, no information was provided in this section.
    Difference
    43%
    Check dated 2024-05-22T21:34:32.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:29:01.000Z thumbnail image

Stay in the know with updates to MND-2119 Long-Term Safety/Efficacy in Hypertriglyceridemia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MND-2119 Long-Term Safety/Efficacy in Hypertriglyceridemia Clinical Trial page.